Naviscan PET Systems

Jonathan S. Batchelor

Nov 14, 2006

2006 11 14 11 59 21 706

Positron emission mammography (PEM) developer Naviscan PET Systems plans to introduce a new design of its high-resolution PET scanner, PEM Flex Solo II, and new image viewing and interpretation software, PEMView, at this year's RSNA conference in Chicago.

Photonics improvements, through the use of lutetium-based crystals, in the new Solo II PEM device yield higher count-rate sensitivity while maintaining resolution capabilities of 1.5-2 mm. In addition, Solo II has added an articulating arm, as well as a motorized C-arm and compression capability, enabling technologists to more easily position patients for optimal views and improved chest wall access, according to the Rockville, MD-based Naviscan.

Naviscan will also introduce PEMView image viewing and interpretation software. The Web-based PEMView incorporates user-configurable image analysis tools, as well as an embedded lexicon for standardized report generation, the company said.

The commercial release of both PEM Flex Solo II and PEMView will be in early 2007.

By Jonathan S. Batchelor
AuntMinnie.com staff writer
November 15, 2006

Copyright © 2006 AuntMinnie.com

IAEA touts radionuclide development activities

March 18, 2025

Imaging Life Issue 20 now available

Imaging Life Issue 20 now available

April 1, 2025

Prostate Imaging

African American men respond more favorably to Ra-223 therapy

December 17, 2024

2024 10 28 Meningioma Thumbnail

Intraarterial PRRT safe in patients with meningioma

October 28, 2024

IAEA touts radionuclide development activities

The IAEA has highlighted its worldwide activities to meet increasing demands for alpha-emitting radionuclides for use in Targeted Alpha Therapy.

March 18, 2025

Kidneys appear to tolerate Lu-177 treatments

Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.

December 19, 2024

African American men respond more favorably to Ra-223 therapy

African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.

December 17, 2024

Prostate Imaging

Intraarterial PRRT safe in patients with meningioma

Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.

October 28, 2024

2024 10 28 Meningioma Thumbnail

NNSA's Mo-99 program: A bumpy ride

Last year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).

October 10, 2024

How effective is Pluvicto in a ‘real-world’ setting?

Pluvicto appears to perform as effectively in prostate cancer patients in “real-world” settings as it did in clinical trials prior to its approval.

September 20, 2024

SNMMI: PET-based protocol shows promise in radioligand therapy

By Amerigo Allegretto

A PET-based scout dosimetry protocol can be feasible in treating lesions with yttrium-90 FAPI (Y-90 FAPI) radioligand therapy.

June 12, 2024

Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.

The rise of theranostics: Part 3 -- What is a theranostics center?

For this third in a series covering the rise of theranostics, AuntMinnie.com asked four doctors of theranostics to discuss the spectrum of freestanding theranostics center development.

June 3, 2024

Part3 Riseof Thernaostics Cover

Can AI improve sustainability in nuclear medicine?

Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet say implementation will require careful consideration of the technology’s benefits and detriments.

April 9, 2024

ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.

The rise of theranostics: Part 2 -- Moving into communities

In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.

April 4, 2024

Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)

SNMMI to tackle Capitol Hill

By AuntMinnie.com staff writers

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) will host its annual Hill Day on April 5 in Washington, DC.

April 3, 2024

The rise of theranostics: Part 1 -- Gaining momentum

FDA-approved radiopharmaceuticals have energized the field of theranostics. In part 1 of a series, experienced theranostics leaders offer implications of the latest clinical trials, how a theranostics clinic works, and advice for introducing theranostics.

March 19, 2024

Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)

Page 1 of 436